Amgen Inc Stock Price, News & Analysis

BetterInvesting Magazine has announced The Walt Disney Co. (NYSE: DIS) as its "Stock to Study" for the August 2025 issue, replacing the previously selected Stride Inc. The decision comes as investors question whether Disney's stock is overvalued or presents a buying opportunity. The magazine will provide comprehensive fundamental data analysis, including sales, earnings, pre-tax profit, and return on equity metrics through the National Association of Investors Corp. The August 2025 issue will also feature a fundamental review of Amgen Inc. (NASDAQ: AMGN), which the Editorial Advisory and Securities Review Committee considers potentially undervalued. The committee, comprising six CFA charterholders and chaired by editor Doron P. Levin, emphasizes that these securities are presented for educational purposes only and should not be considered as endorsed investment recommendations.

Amgen's IMDELLTRA (tarlatamab-dlle) demonstrated remarkable results in the Phase 3 DeLLphi-304 trial for small cell lung cancer (SCLC) treatment. The drug reduced death risk by 40% and extended median overall survival to 13.6 months versus 8.3 months with standard chemotherapy. The trial met both primary overall survival and secondary progression-free survival endpoints. IMDELLTRA showed superior safety profile with lower rates of grade 3+ treatment-related adverse events (27% vs 62%) and fewer discontinuations (3% vs 6%) compared to standard care. The drug also improved patient-reported outcomes for cancer-related symptoms. These results, presented at ASCO 2025 and published in The New England Journal of Medicine, support IMDELLTRA's potential as a transformative second-line treatment for SCLC patients who progressed after platinum-based chemotherapy.

Amgen (NASDAQ:AMGN) has announced its participation in the upcoming Jefferies Global Healthcare Conference on June 4, 2025, at 9:20 a.m. ET. The company will be represented by Peter Griffith, EVP and CFO, and Murdo Gordon, EVP of Global Commercial Operations. The presentation will be accessible via a live webcast on Amgen's website (www.amgen.com) under the Investors section. The webcast recording will remain available for replay for at least 90 days following the event. This presentation is part of Amgen's ongoing investor relations activities where management discusses company developments at various investor and medical conferences.

BetterInvesting Magazine's Editorial Advisory and Securities Review Committee has selected Stride Inc. (NYSE:LRN) as its "Stock to Study" for the August 2025 issue, suggesting potential investment opportunities. The committee will provide a comprehensive analysis of Stride's fundamental data, including sales, earnings, pre-tax profit, and return on equity. Additionally, the magazine will feature a fundamental review of Amgen Inc. (NASDAQ:AMGN), which the committee considers worthy of study from an undervalued perspective. The committee comprises six CFA professionals, with Doron P. Levin serving as chairperson.

Amgen (NASDAQ:AMGN) has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. Kave Niksefat, senior vice president of Global Marketing and Access, will represent the company at the event scheduled for Wednesday, May 21, 2025, at 9:00 a.m. ET.

The presentation will be accessible via webcast to investors, media, and the general public through Amgen's website (www.amgen.com) under the Investors section. The webcast recording will remain available for replay for a minimum of 90 days following the event.

Amgen (NASDAQ:AMGN) has announced its participation in the upcoming Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2025, at 9:20 a.m. PT. The company will be represented by Peter Griffith, executive vice president and CFO, and Jay Bradner, executive vice president of R&D and chief scientific officer.

The presentation will be accessible through a live webcast on Amgen's website (www.amgen.com) under the Investors section. The webcast recording will remain available for replay for at least 90 days following the event.

Amgen (AMGN) reported strong Q1 2025 financial results with total revenues increasing 9% to $8.1B. Product sales grew 11%, driven by 14% volume growth despite 6% lower net selling price. GAAP EPS reached $3.20 compared to a loss of $0.21 in Q1 2024, while non-GAAP EPS increased 24% to $4.90. Fourteen products achieved double-digit sales growth, with notable performers including Repatha® (+27%), EVENITY® (+29%), and TEZSPIRE® (+65%). The new product IMDELLTRA® generated $81M in sales. Operating margin improved, with non-GAAP operating margin increasing 2.5 points to 45.7%. Free cash flow doubled to $1.0B from $0.5B in Q1 2024. However, the company recorded an $800M Otezla® impairment charge.

Amgen (NASDAQ: AMGN) has scheduled its first quarter 2025 financial results announcement for Thursday, May 1, 2025, after market close. The company will host a conference call with the investment community at 4:30 p.m. ET.

Key highlights:

• Leadership Participation: Robert A. Bradway, chairman and chief executive officer, along with other senior management team members will lead the discussion
• Public Access: The event will be accessible to news media, investors, and the general public
• Webcast Details: Live audio will be streamed on www.amgen.com under the Investors section
• Replay Availability: The webcast recording will remain accessible for at least 90 days after the event

Interested parties can find additional information about presentation times and webcast links on Amgen's Investor Relations Events Calendar on their website.

Amgen (NASDAQ: AMGN) has announced a $900 million expansion of its Ohio manufacturing facility, which will create 350 new jobs, bringing the total employment to 750 positions and total investment in Central Ohio to over $1.4 billion.

The expansion builds upon Amgen's initial entry into Ohio in June 2021, when it established a state-of-the-art biomanufacturing facility that created 400 jobs. This investment is part of Amgen's broader U.S. manufacturing strategy, which includes nearly $5 billion in direct capital expenditures since 2017, generating approximately $12 billion in additional downstream output to the U.S. economy.

The Ohio expansion enhances Amgen's global biomanufacturing network and follows the company's recent announcement of a $1 billion investment for a second manufacturing plant in Holly Springs, NC.